South Carolina is currently home to 1163 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Columbia and Spartanburg. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06736041
Recruiting
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20-valent pneumococcal vaccine (Prevnar 20, licensed pneumococcal conjugate vaccine) when they are administered with routine pediatric vaccines in infants aged from approximately 2 months (42 to 89 days). The study duration per... Read More
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
07/07/2025
Locations: Tribe Clinical Research - Greenville - Verdae Boulevard- Site Number : 8400005, Greenville, South Carolina
Conditions: Pneumococcal Immunization
Register for Updates
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132
Recruiting
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combination treatments in adult participants with locally advanced/metastatic CEACAM5 expressing tumors. There will be 3 substudies under this Master Protocol that... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Prisma Health Cancer Institute, ITOR, CRU, Greenville, South Carolina
Conditions: Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
Register for Updates
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779
Recruiting
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: AUC Urologists, LLC, Myrtle Beach, South Carolina
Conditions: Metastatic Castration-Resistant Prostate Cancer
Register for Updates
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
NCT06562543
Recruiting
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib f... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Colorectal Cancer
Register for Updates
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
NCT06423430
Recruiting
The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
07/07/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Treatment Resistant Depression
Register for Updates
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
NCT06377852
Recruiting
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs. The primary objective of the CDK Study is to compare time to treatment discontinuation (TTD) on the approved dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle) or ribociclib (600 mg orally... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/07/2025
Locations: Levine Cancer Institute, Rock Hill, South Carolina
Conditions: Metastatic Breast Cancer
Register for Updates
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744
Recruiting
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: MUSC Hollings Cancer Center /ID# 259604, Charleston, South Carolina
Conditions: Follicular Lymphoma (FL)
Register for Updates
Induction in the Dark
NCT06144177
Recruiting
This study will enroll children ages 2-6 who are undergoing an elective outpatient surgical procedure under general anesthesia. They will be randomized to one of the following groups and assessed for preoperative anxiety, mask acceptance, and behavioral changes in the following week. 1. darkened room and star projector with parental presence; 2. preoperative midazolam 0.5 mg/kg by mouth and parental presence; or 3. parental presence alone.
Gender:
ALL
Ages:
Between 2 years and 6 years
Trial Updated:
07/07/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Anesthesia Induction
Register for Updates
Hypermobile Ehlers-Danlos Syndrome - Transcutaneous Auricular Neuromodulation
NCT06105541
Recruiting
Investigate whether at-home transcutaneous auricular VNS (tAN: transcutaneous auricular neurostimulation) improves a battery of nine key physical and psychological symptoms of a group of hEDS (Hypermobile Ehlers-Danlos Syndrome \& Hypermobile Spectrum Disorder) patients (n=30) using a randomized, double blind, sham controlled design. The study team will collect clinical measures at baseline, after a two-week double-blind intervention phase, after a following two-week open-label phase and finally... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/07/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Hypermobile Ehlers-Danlos Syndrome, Hypermobile Spectrum Disorder, Ehlers-Danlos Syndrome
Register for Updates
No Opioids vs. Minimal Opioids Following Inguinal Hernia Repair
NCT05929937
Recruiting
The investigators hypothesize that not prescribing opioids after uncomplicated, outpatient IHR will be non-inferior to prescribing opioids (5 tablets of Oxycodone, 5mg; or surgeon preference for intolerance) with respect to requests for opioid refills. Additionally, the investigators believe there will be no significant difference in postoperative readmission for pain quality of life at 30 days in either group.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Prisma Health, Greenville, South Carolina
Conditions: Postoperative Pain, Inguinal Hernia
Register for Updates
Direct Access Carotid Artery Stenting Using the Neuroguard IEP System (PERFORMANCE III)
NCT05845710
Recruiting
The PERFORMANCE III study is a prospective, multicenter single-arm, open label study to evaluate the safety and effectiveness of the Neuroguard IEP® Direct System for the treatment of carotid artery stenosis in subjects at elevated risk for carotid endarterectomy (CEA). Eligible patients greater than or equal to 20 years of age and less than or equal to 80 years of age, are those who have been diagnosed with either de-novo atherosclerotic or post CEA restenotic lesion(s) in the internal carotid... Read More
Gender:
ALL
Ages:
Between 20 years and 80 years
Trial Updated:
07/07/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Carotid Stenosis, Carotid Artery Diseases
Register for Updates
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797
Recruiting
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Medical University of South Carolina (MUSC), Charleston, South Carolina
Conditions: Multiple Myeloma
Register for Updates